Antonella Chadha Santuccione

Antonella Chadha Santuccione has a long and impressive career in medical science. Antonella began their career in 2005 as a Postdoctoral Fellow/ Residency in Pathology at UniversitätsSpital Zürich. In 2006, they moved to the University of Zurich and worked as a Medical Doctor, Group Leader, Clinical Pathologist, and Neuroscientist. In 2012, they joined Roche Pharmaceuticals as a Medical Manager Psychiatry, CNS, and Medical Affairs. In this role, they drove market launch readiness initiatives for a new psychiatry product, including a large scale collaboration with therapeutic area experts as well as conceptualization of clinical studies. Antonella also systematically assessed all new psychiatry medical development plans from a German market perspective to optimize global Phase IV trial designs. In 2014, they became a Clinical Reviewer at Schweizerisches Heilmittelinstitut, Swissmedic. In 2018, they joined Roche Diagnostics Europe as a Senior Medical Director Alzheimer's Disease. In 2020, they were appointed Head Stakeholder Liaison Alzheimer's Disease Biogen and Medical Director for Partnership in Alzheimer's at Roche. Additionally, they are the Vice President pro bono at Euresearch and the Chief Medical Officer at Altoida, Inc., starting in 2022. Previously, they held the role of Co-Founder and CEO at Women's Brain Project from 2016.

Antonella Chadha Santuccione obtained their Doctor of Medicine (M.D.) from the University of Zurich in 2006, majoring in Psychiatric/Mental Health/Neuroscience. In 2011, they obtained an Advanced Studies in Trial Management in Clinical Research certification from the University of Zurich.